X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs IPCA LABS - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON IPCA LABS BIOCON /
IPCA LABS
 
P/E (TTM) x 41.0 30.8 133.1% View Chart
P/BV x 7.1 4.5 156.7% View Chart
Dividend Yield % 0.2 0.1 157.5%  

Financials

 BIOCON    IPCA LABS
EQUITY SHARE DATA
    BIOCON
Mar-18
IPCA LABS
Mar-18
BIOCON /
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,188695 170.8%   
Low Rs305400 76.3%   
Sales per share (Unadj.) Rs68.7260.2 26.4%  
Earnings per share (Unadj.) Rs7.619.0 39.8%  
Cash flow per share (Unadj.) Rs14.033.1 42.3%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %0.10.2 73.4%  
Book value per share (Unadj.) Rs86.3213.0 40.5%  
Shares outstanding (eoy) m600.00126.20 475.4%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.92.1 516.0%   
Avg P/E ratio x98.928.9 342.4%  
P/CF ratio (eoy) x53.416.6 322.5%  
Price / Book Value ratio x8.62.6 336.3%  
Dividend payout %13.25.3 251.2%   
Avg Mkt Cap Rs m447,90069,120 648.0%   
No. of employees `0006.113.3 46.4%   
Total wages/salary Rs m9,3117,359 126.5%   
Avg. sales/employee Rs Th6,705.82,477.4 270.7%   
Avg. wages/employee Rs Th1,514.2555.2 272.7%   
Avg. net profit/employee Rs Th736.9180.6 407.9%   
INCOME DATA
Net Sales Rs m41,23432,836 125.6%  
Other income Rs m2,062418 493.3%   
Total revenues Rs m43,29633,254 130.2%   
Gross profit Rs m8,2914,505 184.0%  
Depreciation Rs m3,8511,777 216.7%   
Interest Rs m615240 256.0%   
Profit before tax Rs m5,8872,905 202.6%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,569511 307.0%   
Profit after tax Rs m4,5312,394 189.2%  
Gross profit margin %20.113.7 146.6%  
Effective tax rate %26.717.6 151.5%   
Net profit margin %11.07.3 150.7%  
BALANCE SHEET DATA
Current assets Rs m41,48619,455 213.2%   
Current liabilities Rs m21,41310,076 212.5%   
Net working cap to sales %48.728.6 170.4%  
Current ratio x1.91.9 100.3%  
Inventory Days Days6498 65.3%  
Debtors Days Days9467 140.7%  
Net fixed assets Rs m50,66120,260 250.1%   
Share capital Rs m3,000252 1,188.6%   
"Free" reserves Rs m48,80826,633 183.3%   
Net worth Rs m51,80826,886 192.7%   
Long term debt Rs m17,8982,340 764.8%   
Total assets Rs m99,89741,173 242.6%  
Interest coverage x10.613.1 80.7%   
Debt to equity ratio x0.30.1 396.9%  
Sales to assets ratio x0.40.8 51.8%   
Return on assets %5.26.4 80.5%  
Return on equity %8.78.9 98.2%  
Return on capital %9.610.8 89.5%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m12,05815,642 77.1%   
Fx outflow Rs m7,3484,884 150.5%   
Net fx Rs m4,71010,759 43.8%   
CASH FLOW
From Operations Rs m6,6213,411 194.1%  
From Investments Rs m-6,840-1,354 505.2%  
From Financial Activity Rs m-2,397-1,304 183.8%  
Net Cashflow Rs m-2,612753 -346.8%  

Share Holding

Indian Promoters % 40.4 45.9 88.0%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 11.4 73.7%  
FIIs % 10.7 25.3 42.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.4 114.4%  
Shareholders   109,995 36,892 298.2%  
Pledged promoter(s) holding % 0.0 2.1 1.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare BIOCON With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Apr 18, 2019 (Close)

TRACK BIOCON

BIOCON - GSK PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS